Oncology: Ariana's analysis identifies predictive biomarker signatures for anti-MET therapy in solid tumors.

This case study demonstrates how Ariana Pharmaceuticals’ KEM® Explainable AI technology uncovered a hidden responder signature during the early clinical development of ARGX-111, an anti-MET monoclonal antibody for solid tumors, enabling Argenx to make a pivotal strategic decision that ultimately led to the development of ARGX-113 (efgartigimod, Vyvgart®).
Using multidimensional clinical and biomarker data from a Phase I dose-escalation study involving 17 patients, KEM® explored complex relationships between patient characteristics, cytokine profiles, pharmacokinetic data, and clinical outcomes. While the overall clinical activity of ARGX-111 appeared limited, Ariana’s analysis revealed a small but highly responsive patient subgroup and identified inflammatory biomarkers predictive of efficacy and adverse events.
These insights improved understanding of the drug’s mechanism of action and informed Argenx’s strategic pivot toward developing ARGX-113, which subsequently became the blockbuster medicine Vyvgart®.

- ● Identified a small but highly responsive patient subgroup at dose level #3 through biomarker-driven patient stratification.
- ● Revealed a pre-inflammatory cytokine profile strongly predictive of anti-tumor efficacy and adverse events.
- ● Improved mechanistic understanding of ARGX-111 by demonstrating limited cellular activity despite evidence of response in selected patients.
- ● Enabled Argenx to strategically redirect its antibody development program toward ARGX-113.
- ● Contributed to the early scientific foundation supporting the development of Vyvgart®, now approved globally for multiple autoimmune indications.

- ● Identify biomarkers associated with efficacy and safety in patients treated with ARGX-111.
- ● Discover patient selection biomarkers capable of identifying responders.
- ● Characterize cytokine signatures associated with therapeutic response and adverse events.
- ● Improve understanding of ARGX-111’s mechanism of action to support future drug development decisions.

● Phase I dose-escalation study evaluating ARGX-111, an anti-MET monoclonal antibody for solid tumors.
● 17 patients included in the clinical analysis.
● Clinical variables included patient characteristics, cytokine measurements, dose information, pharmacokinetic (PK) data, and safety observations.
● Analysis incorporated 165 variables together with preclinical data from 40 animal studies.
● 12 predefined efficacy endpoints assessed across treatment groups.

- ● KEM® Explainable AI explored 2,719 logical relationships between biomarkers, clinical variables, efficacy, and safety outcomes.
- ● Association-rule mining identified biomarker combinations predictive of treatment response and toxicity.
- ● Explainable analysis enabled identification of responder signatures and mechanistic relationships between cytokines and clinical outcomes.
● Results were presented as transparent, interpretable biomarker networks to support scientific and clinical decision-making.

● Ariana’s KEM® platform identified a small but highly responsive patient subgroup at dose level #3.
●The analysis demonstrated that ARGX-111 produced limited cellular activity (lymphocytes/monocytes), helping explain the modest overall clinical efficacy observed during the study.
● A pre-inflammatory cytokine profile was identified as highly predictive of anti-tumor efficacy and adverse events, providing valuable insight into patient response.
● The biomarker findings significantly improved understanding of the biological mechanisms underlying treatment response and safety.
● These insights enabled Argenx to optimize the design of its next-generation antibody program (ARGX-113), leading to a strategic pivot in its clinical pipeline.

● Ariana’s analysis informed the scientific understanding that supported Argenx’s decision to prioritize ARGX-113 over continued development of ARGX-111.
●ARGX-113 (efgartigimod) was subsequently developed into Vyvgart®, now approved in multiple autoimmune diseases, including generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP).
● Vyvgart® has become Argenx’s flagship product and a multi-billion-dollar commercial success, validating the strategic direction established during the early biomarker analyses.